<DOC>
	<DOCNO>NCT00719407</DOCNO>
	<brief_summary>The purpose study determine safety pharmacokinetics moderate high dos erythropoietin newborn infant birth asphyxia .</brief_summary>
	<brief_title>Neonatal Erythropoietin Asphyxiated Term Newborns</brief_title>
	<detailed_description>Newborn infant birth asphyxia high risk death long-term neurologic disability ; yet therapy birth asphyxia currently limit . Erythropoietin ( Epo ) FDA-approved drug effective neuroprotective agent animal model birth asphyxia . This phase I dose find multi-center trial test safety pharmacokinetics Epo human infant birth asphyxia . The long-term objective propose research reduce mortality decrease risk long-term disability infant survive beyond newborn period .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Hypoxia-Ischemia , Brain</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . â‰¥ 36 week gestational age 2 . Perinatal depression ( low Apgar score , need resuscitation ) 3 . Moderate severe encephalopathy 1 . Specific aEEG finding 2 . Intrauterine growth restriction 3 . Severe congenital anomaly , genetic syndrome , metabolic disorder , arthrogryposis , TORCH infection 4 . Microcephaly 5 . Infant old 23.5 hour age time consent 6 . Infant judge attend physician likely die due severity illness 7 . Polycythemia 8 . Hypertension 9 . No indwelling line</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Hours</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>birth asphyxia</keyword>
	<keyword>neonatal encephalopathy</keyword>
	<keyword>hypoxic-ischemic encephalopathy</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>neonate</keyword>
</DOC>